Last edition
News about
Arch Biopartners Advances Phase II Trial of LSALT Peptide as New Site Begins Patient Dosing
Arch Biopartners advances LSALT peptide trial for acute kidney injury as new clinical site initiates patient dosing and global expansion plans progress.
GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer
Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.
Caris Study Shows AI Tool Improves Accuracy in Lung Cancer Diagnosis
Caris Life Sciences finds its GPSai algorithm can identify misdiagnosed lung cancer cases, potentially improving treatment decisions and outcomes through AI-driven molecular profiling.
Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy
Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.
FDA Accepts Ionis' Zilganersen NDA for Priority Review in AxD
Ionis’ zilganersen NDA for Alexander disease has been accepted by the FDA for Priority Review, with a PDUFA target action date set for 22nd September, 2026, marking a key regulatory milestone for the potential treatment.
CVC and Apollo Partner to Accelerate Syntegon's Next Growth Phase
CVC has reaffirmed its confidence in Syntegon’s growth strategy as Apollo acquires a 37 percent minority stake to support expansion—particularly in the US—following strong performance that saw revenue reach a record €1.75 billion and operating profit quadruple, with further growth planned under CEO Torsten Türling.
The acquisition marks a significant strategic move for Abbott, enabling the company to expand into high-growth segments of cancer screening and diagnostics.
Innovent Doses First Patient in Phase III Trial of Tigulixostat for Gout
Innovent initiates Phase III study of tigulixostat against febuxostat in Chinese gout patients, aiming to deliver improved uric acid control and better safety outcomes.
Co-Diagnostics Expands CoSara's South Asia Footprint, Targets USD 13 Billion Diagnostics Market
Co-Diagnostics, Inc. has announced a strategic expansion of its South Asia operations through its joint venture CoSara Diagnostics Pvt. Ltd., formed in partnership with Ambalal Sarabhai Enterprises Limited.
From Generics to Biologics: Semaglutide Reshapes Pharma Manufacturing in India
The recent developments around semaglutide in India—triggered by patent expiry and rapid domestic entry—are poised to significantly reshape the country’s pharmaceutical manufacturing landscape.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy